CN116832054A - 一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 - Google Patents
一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 Download PDFInfo
- Publication number
- CN116832054A CN116832054A CN202310579049.6A CN202310579049A CN116832054A CN 116832054 A CN116832054 A CN 116832054A CN 202310579049 A CN202310579049 A CN 202310579049A CN 116832054 A CN116832054 A CN 116832054A
- Authority
- CN
- China
- Prior art keywords
- water
- soluble dietary
- dietary fiber
- ellagic acid
- urolithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002079 Ellagic acid Polymers 0.000 title claims abstract description 121
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 title claims abstract description 121
- 229960002852 ellagic acid Drugs 0.000 title claims abstract description 121
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 title claims abstract description 120
- 235000004132 ellagic acid Nutrition 0.000 title claims abstract description 120
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 96
- 230000004060 metabolic process Effects 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- RIUPLDUFZCXCHM-UHFFFAOYSA-N Urolithin A Chemical compound OC1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 RIUPLDUFZCXCHM-UHFFFAOYSA-N 0.000 title abstract description 90
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229920001202 Inulin Polymers 0.000 claims abstract description 22
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 22
- 229940029339 inulin Drugs 0.000 claims abstract description 22
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 20
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 20
- 239000000679 carrageenan Substances 0.000 claims abstract description 20
- 229920001525 carrageenan Polymers 0.000 claims abstract description 20
- 229940113118 carrageenan Drugs 0.000 claims abstract description 20
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 20
- 239000001814 pectin Substances 0.000 claims abstract description 20
- 235000010987 pectin Nutrition 0.000 claims abstract description 20
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 20
- 239000001259 polydextrose Substances 0.000 claims abstract description 20
- 229940035035 polydextrose Drugs 0.000 claims abstract description 20
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 20
- 239000000661 sodium alginate Substances 0.000 claims abstract description 20
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 20
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 20
- 229920001277 pectin Polymers 0.000 claims abstract description 19
- 229920001615 Tragacanth Polymers 0.000 claims abstract description 18
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 18
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 18
- 239000000230 xanthan gum Substances 0.000 claims abstract description 18
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 18
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 17
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 17
- 229920001353 Dextrin Polymers 0.000 claims abstract description 17
- 239000004375 Dextrin Substances 0.000 claims abstract description 17
- 229920002148 Gellan gum Polymers 0.000 claims abstract description 17
- 229920002907 Guar gum Polymers 0.000 claims abstract description 17
- 235000019425 dextrin Nutrition 0.000 claims abstract description 17
- 235000010492 gellan gum Nutrition 0.000 claims abstract description 17
- 239000000216 gellan gum Substances 0.000 claims abstract description 17
- 235000010417 guar gum Nutrition 0.000 claims abstract description 17
- 239000000665 guar gum Substances 0.000 claims abstract description 17
- 229960002154 guar gum Drugs 0.000 claims abstract description 17
- 239000000305 astragalus gummifer gum Substances 0.000 claims abstract description 16
- 229920000084 Gum arabic Polymers 0.000 claims abstract description 11
- 235000010489 acacia gum Nutrition 0.000 claims abstract description 11
- 239000000205 acacia gum Substances 0.000 claims abstract description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 10
- 244000215068 Acacia senegal Species 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 5
- 230000032683 aging Effects 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 230000003902 lesion Effects 0.000 claims abstract description 5
- 235000020824 obesity Nutrition 0.000 claims abstract description 5
- 229930186301 urolithin Natural products 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 210000003608 fece Anatomy 0.000 abstract description 49
- 241000699670 Mus sp. Species 0.000 abstract description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 229960000292 pectin Drugs 0.000 description 17
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 11
- 229940107187 fructooligosaccharide Drugs 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 7
- 241000220479 Acacia Species 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 6
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- WXUQMTRHPNOXBV-UHFFFAOYSA-N Urolithin B Chemical compound C1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 WXUQMTRHPNOXBV-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940023476 agar Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 229920001968 ellagitannin Polymers 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- WDGSXHQNUPZEHA-UHFFFAOYSA-N 3,9-dihydroxybenzo[c]chromen-6-one Chemical compound C1=C(O)C=C2C3=CC=C(O)C=C3OC(=O)C2=C1 WDGSXHQNUPZEHA-UHFFFAOYSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 229920001301 Hexahydroxydiphenic acid Polymers 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MFTSECOLKFLUSD-UHFFFAOYSA-N hexahydroxydiphenic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(O)C=C1C(O)=O MFTSECOLKFLUSD-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素A的药物中的应用和药物组合物,属于生物药物技术领域。本发明提供的水溶性膳食纤维,包括以下至少两种组分:结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β‑葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉。本发明中将上述不同组合的水溶性膳食纤维和鞣花酸复配饲喂小鼠,能显著小鼠粪便中尿石素A的平均含量。可见,所述水溶性膳食纤或与鞣花酸组合能改善机体鞣花酸代谢类型,提高尿石素A的含量,为糖尿病、肥胖、衰老以及神经中枢病变等治疗提供了新手段。
Description
技术领域
本发明属于生物药物技术领域,具体涉及一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素A的药物中的应用和药物组合物。
背景技术
鞣花酸是一种天然多酚,在自然界中以鞣花单宁的形式存在于浆果(石榴,草莓等)和坚果(核桃,栗子等)中,来源广泛,提取方便。在胃肠道中鞣花单宁被水解释放六羟基二苯酸并迅速缩合成鞣花酸。鞣花酸是一种强极性分子,几乎无法被胃肠道吸收利用。因此,鞣花酸本身的生物利用度低,无法发挥有效的生物活性。人体肠道内具有特定的菌群能够有效代谢鞣花酸并产生一系列尿石素,相比于鞣花酸,尿石素能够被有效利用并产生一系列益生活性,日本专利JP2022190124研究表明尿石素A在糖尿病,肥胖,衰老以及神经中枢病变的小鼠模型中的均能发挥益生活性,因此,作为尿石素的前体物质,鞣花酸因其来源广泛其易于提取,在食品领域得到广泛关注。
现有研究表明,鞣花酸在结肠中代谢可以产生不同的尿石素衍生物。其中,尿石素A,异构尿石素A以及尿石素B为鞣花酸代谢的终产物。根据不同人群代谢EA终产物的不同,可以将人群的鞣花酸的代谢类型分为A型、B型和0型;A型人群最终产生尿石素A,B型人群产生尿石素A、尿石素B和异构尿石素A,0型人群则无法代谢鞣花酸产生尿石素(Tomás-BarberánF A,Garcia-Villalba R,Gonzalez-Sarrias A,et al.Ellagic acid metabolism byhuman gut microbiota:consistent observation of three urolithin phenotypes inintervention trials,independent of food source,age,and health status[J].Journal ofAgricultural and Food Chemistry,2014,62(28):6535-6538.)。因此,在0型人群中,鞣花酸无法被代谢成尿石素A产生有效的益生活性,而在B型人群中,尿石素A产量降低,无法达到有效剂量。这使得鞣花酸在0型和B型人群中应用受限。人群代谢终产物的差异主要和人群肠道菌群组成差异有关,因此,亟需开发一种改善0型和B型人群鞣花酸代谢转化的方法。
与多糖复配能有效提高鞣花酸生物活性:CN113812629公布了一种淀粉-鞣花酸包结组合物的制备方法及其再抗氧化食品中的应用,通过将鞣花酸和淀粉高速研磨形成组合物,该组合物具有较好的缓释性能及体外抗氧化活性。CN115191540公开了一种含鞣花酸的组合物及其制备方法和用途,采用壳寡糖、菊糖、鞣花酸制备复合物,并能够有效抑制胃癌细胞及肠癌细胞生长。CN111107908公布了包括鞣花酸化合物的组合物,采用不同甘油磷脂以及金属氧化物与鞣花酸复配,提高鞣花酸的抗氧化性,并提高了组合物整体的稳定性。然而,目前尚无关于多糖与鞣花酸复配,促进鞣花酸代谢的报道。
膳食纤维是公认的人类健康营养素。先前的研究证明,膳食纤维通过调节肠道微生物群对胃肠健康具有重要意义。此外,机理研究表明,不同膳食纤维的生理功能在很大程度上取决于它们的物理化学特性,其中之一是溶解度。与不溶性膳食纤维相比,可溶性膳食纤维很容易被肠道中的纤维降解微生物获取和代谢,并产生一系列有益和功能性的代谢产物。鉴于鞣花酸在体内被代谢为尿石素A的效果较低,且目前还未有关于能改善鞣花酸代谢为尿石素A的膳食纤维的报道。
发明内容
有鉴于此,本发明的目的在于提供一种水溶性膳食纤维,通过将不同类型的可溶性膳食纤维组合来改善肠道菌群结构,从而促进鞣花酸代谢为尿石素A的效率。
本发明提供了一种水溶性膳食纤维,包括以下至少两种组分:结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉。
优选的,包括以下至少一组:结冷胶、瓜尔胶和卡拉胶形成的第一水溶性膳食纤维,低聚果糖、低聚木糖和低聚异麦芽糖形成的第二水溶性膳食纤维,果胶、β-葡聚糖和聚葡萄糖形成的第三水溶性膳食纤维,海藻酸钠、阿拉伯胶和抗性糊精形成的第四水溶性膳食纤维和黄原胶、黄蓍胶和菊粉形成的第五水溶性膳食纤维;
所述第一水溶性膳食纤维、第二水溶性膳食纤维、第三水溶性膳食纤维、第四水溶性膳食纤维或第五水溶性膳食纤维中三种组分的质量比依次为1~3:1~3:1~3。
本发明提供了一种促进鞣花酸代谢为尿石素A的药物组合物,包括所述水溶性膳食纤维和鞣花酸;
所述水溶性膳食纤维和鞣花酸的质量比为(100~250):3。
优选的,所述水溶性膳食纤维和鞣花酸的质量比为250:3。
优选的,所述鞣花酸的结构式如式I所示:
本发明提供了所述水溶性膳食纤维或所述药物组合物在制备促进鞣花酸代谢为尿石素A的药物中的应用。
本发明提供了一种促进鞣花酸代谢为尿石素A的产品,以所述水溶性膳食纤维或所述药物组合物为活性成分,还包括辅料。
优选的,所述产品包括以下至少一种:药物、保健品和保健食品。
本发明提供了所述水溶性膳食纤维或所述药物组合物在制备预防和/或治疗以下至少一种疾病的药物中的应用:糖尿病、肥胖、衰老和神经中枢病变。
优选的,所述疾病的患者属于鞣花酸代谢A型人群、B型人群和/或0型人群。
本发明提供了一种水溶性膳食纤维,包括以下至少两种组分:结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉。本发明从众多的水溶性膳食纤维中通过筛选优化获得了多种具有影响鞣花酸代谢类型的组分。本发明中将上述不同类型的水溶性膳食纤维和鞣花酸组合饲喂小鼠,监测小鼠鞣花酸代谢情况,结果表明小鼠粪便中尿石素A的平均含量从41.0~32.3μg/g粪便(对照组,仅饲喂鞣花酸)提高至41.4~87.4μg/g粪便。可见,不同种类水溶性膳食纤维的组合有利于提高机体内鞣花酸代谢为尿石酸A的水平,为通过尿石酸A治疗多种疾病提供了新的手段,具有重要的临床疾病治疗意义。
进一步的,本发明具体限定了若干个水溶性膳食纤维的组合方案,不同种类的水溶性膳食纤维组合对鞣花酸代谢类型的影响程度是不用的,其中黄原胶、黄蓍胶和菊粉形成的第五水溶性膳食纤维提高鞣花酸代谢为尿石素A的含量方面效果最佳,其次为低聚果糖、低聚木糖和低聚异麦芽糖形成的第二水溶性膳食纤维。
附图说明
图1为具有促进鞣花酸代谢为尿石素A的水溶性膳食纤维的筛选结果;
图2为实施例2、3、4、5和6中不同组合的水溶性膳食纤维促进鞣花酸代谢为尿石素A的含量变化图;其中与对照组比较,*p<0.05,**p<0.01,***p<0.001,****p<0.0001。
具体实施方式
本发明提供了一种水溶性膳食纤维,包括以下至少两种组分:结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉。
在本发明中,所述水溶性膳食纤维优选包括以下至少一组:结冷胶、瓜尔胶和卡拉胶形成的第一水溶性膳食纤维,低聚果糖、低聚木糖和低聚异麦芽糖形成的第二水溶性膳食纤维,果胶、β-葡聚糖和聚葡萄糖形成的第三水溶性膳食纤维,海藻酸钠、阿拉伯胶和抗性糊精形成的第四水溶性膳食纤维和黄原胶、黄蓍胶和菊粉形成的第五水溶性膳食纤维,更优选为第二水溶性膳食纤维和第五水溶性膳食纤维,最优选为第五水溶性膳食纤维。所述第一水溶性膳食纤维、第二水溶性膳食纤维、第三水溶性膳食纤维、第四水溶性膳食纤维或第五水溶性膳食纤维中三种组分的质量比依次优选为1~3:1~3:1~3,更优选为1:1:1。本发明对上述水溶性膳食纤维的来源没有特殊限制,采用本领域技术人员所熟知的水溶性膳食纤维的来源即可。在本发明实施例中,所述结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉购自Sigma。
在本发明实施例中,对众多种水溶性膳食纤维进行筛选发现,不同水溶性膳食纤维的组合能够明显影响鞣花酸代谢为尿石素A的效率。例如,从结冷胶、瓜尔胶、卡拉胶、琼脂、明胶、低聚果糖、低聚木糖、低聚异麦芽糖、低聚半乳糖、果胶、壳聚糖、β-葡聚糖、聚葡萄糖、木聚糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉20种膳食纤维中进行动物实验筛选,发现结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉这15种膳食纤维能够促进小鼠体内鞣花酸代谢。
本发明提供了一种促进鞣花酸代谢为尿石素A的药物组合物,包括所述水溶性膳食纤维和鞣花酸;所述水溶性膳食纤维和鞣花酸的质量比为(100~250):3。所述水溶性膳食纤维和鞣花酸的质量比优为250:3。
在本发明中,所述药物组合物中,所述水溶性膳食纤维通过改善机体内肠道益生菌的结构,从而改善鞣花酸代谢为尿石素A的效率。所述鞣花酸作为代谢底物存在。所述鞣花酸可提取自石榴、黑莓、草莓、石榴、枸杞、覆盆子、白橡实、蔓越莓、山核桃的一种或几种。所述鞣花酸的结构式优选如式I所示,购自Sigma公司。
本发明提供了所述水溶性膳食纤维或所述药物组合物在制备促进鞣花酸代谢为尿石素A的药物中的应用。
本发明实施例结果证明,结冷胶、瓜尔胶、卡拉胶与鞣花酸组合饲喂小鼠,监测小鼠鞣花酸代谢情况,结果表明小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至59.1μg/g粪便;果胶、β-葡聚糖、聚葡萄糖与鞣花酸组合饲喂小鼠,小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至63.5μg/g粪便。海藻酸钠、阿拉伯胶、抗性糊精与鞣花酸组合饲喂小鼠,小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至62.4μg/g粪便。低聚果糖、低聚木糖、低聚异麦芽糖与鞣花酸组合饲喂小鼠使小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至77.1μg/g粪便。黄原胶、黄蓍胶、菊粉与鞣花酸组合饲喂小鼠使小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至87.4μg/g粪便。
本发明提供了一种促进鞣花酸代谢为尿石素A的产品,以所述水溶性膳食纤维或所述药物组合物为活性成分,还包括辅料。
在本发明中,优选的,所述产品包括以下至少一种:药物、保健品和保健食品。在本发明实施例中,所述药物组合物作为添加剂添加到动物饲料中,制备得到能够促进小鼠鞣花酸代谢为尿石素A的药物饲料。在本发明中,所述药物优选以鞣花酸以不低于5mg/kg体重的日剂量提供给人群。所述鞣花酸以60mg/kg体重的日剂量提供给小鼠,所述水溶性膳食纤维以5000mg/kg体重的日剂量提供给小鼠。
鉴于通过尿石素A能够达到多种疾病的治疗目的,本发明提供了所述水溶性膳食纤维或所述药物组合物在制备预防和/或治疗以下至少一种疾病的药物中的应用:糖尿病、肥胖、衰老和神经中枢病变。
在本发明中,所述疾病的患者优选属于鞣花酸代谢A型人群、B型人群和/或0型人群。
本发明对所述药物的剂型和制备方法均没有特殊限制,采用本领域所熟知的药物的剂型和制备方法即可。
下面结合实施例对本发明提供的一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素A的药物中的应用和药物组合物进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
从众多水溶性膳食纤维中优化筛选具有促进鞣花素代谢为尿石素A功能的成分的方法
选取168只代谢型为A型的SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,结冷胶、瓜尔胶、卡拉胶、琼脂、明胶、低聚果糖、低聚木糖、低聚异麦芽糖、低聚半乳糖、果胶、壳聚糖、β-葡聚糖、聚葡萄糖、木聚糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉的添加比例为5%。将小鼠随机分为21组(n=8),对照组饲喂7天只含有鞣花酸的Ain93G饲料。其余组分别饲喂7天含有鞣花酸和其中一种上述膳食纤维的混合饲料。实验最后一天收集小鼠粪便,监测小鼠鞣花酸代谢情况。
结果表明,20种膳食纤维种结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉能有效促进小鼠体内鞣花酸代谢。
实施例2
结冷胶、瓜尔胶、卡拉胶与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,结冷胶、瓜尔胶、卡拉胶的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂含结冷胶、瓜尔胶、卡拉胶(质量比为1:1:1)和鞣花酸的饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。将小鼠粪便按照质量体积比1:10加入二甲基亚砜中,研磨仪研磨充分后,4℃,8000rpm离心10min,上清液过0.22μm有机膜后进行HPLC检测。尿石素A的HPLC检测方法如下:
液相色谱仪为Waters e2695色谱仪,检测器为Waters 2489紫外-可见光检测器,检测波长为305nm,色谱柱为Eclipse XDB-C18色谱柱(250mm×4.6mm,5.0μm;Agilent),柱温为30℃,进样量为10μL,洗脱速度为1.0mL/min;
流动相为含0.5%甲酸的水溶液(A)和乙腈(B)。即,A由0.5%甲酸和99.5%的双蒸水组成,B由100%乙腈组成,%为体积%;
洗脱梯度:0-20min,5%-25%B;20-25min,25%-70%B;25-26min,70%-5%B;26-35min,5%B。
结果表明,小鼠粪便中尿石素A的平均含量从32.3μg/g粪便提升至59.1μg/g粪便(p<0.05)。
实施例3
低聚果糖、低聚木糖、低聚异麦芽糖与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,低聚果糖、低聚木糖、低聚异麦芽糖的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂含低聚果糖、低聚木糖、低聚异麦芽糖(质量比为1:1:1)和鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
结果表明,小鼠粪便中尿石素A的平均含量从30.3μg/g粪便提升至77.1μg/g粪便(p<0.0001)。
实施例4
果胶、β-葡聚糖、聚葡萄糖与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,果胶、β-葡聚糖、聚葡萄糖的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂果胶、β-葡聚糖、聚葡萄糖(质量比为1:1:1)与鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
结果表明,小鼠粪便中尿石素A的平均含量从14.0μg/g粪便提升至63.5μg/g粪便(p<0.01)。
实施例5
海藻酸钠、阿拉伯胶、抗性糊精与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,海藻酸钠、阿拉伯胶、抗性糊精的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂海藻酸钠、阿拉伯胶、抗性糊精(质量比为1:1:1)与鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
发现小鼠粪便中尿石素A的平均含量从22.5μg/g粪便提升至62.4μg/g粪便(p<0.05)。
实施例6
黄原胶、黄蓍胶、菊粉与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,黄原胶、黄蓍胶、菊粉的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂黄原胶、黄蓍胶、菊粉(质量比为1:1:1)与鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
结果表明,小鼠粪便中尿石素A的平均含量从23.4μg/g粪便提升至87.4μg/g粪便(p<0.05)。
实施例7
菊粉、聚葡萄糖、海藻酸钠与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,菊粉、聚葡萄糖、海藻酸钠的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂菊粉、聚葡萄糖、海藻酸钠(质量比为1:1:1)与鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
结果表明,小鼠粪便中尿石素A的平均含量从19.8μg/g粪便提升至41.4μg/g粪便(p<0.05)。
实施例8
卡拉胶、低聚果糖、果胶与鞣花酸组合
选取40只SPF级C57BL/6小鼠,使用Ain93G纯化饲料作为基础饲料。鞣花酸的添加比例为0.06%,卡拉胶、低聚果糖、果胶的添加比例为5%,前7天每天饲喂只含有鞣花酸的Ain93G饲料,后7天中,每天饲喂卡拉胶、低聚果糖、果胶(质量比为1:1:1)与鞣花酸的混合饲料。实验过程中每7天收集小鼠粪便,监测小鼠鞣花酸代谢情况。尿石素A的HPLC检测方法同实施例2。
结果表明,小鼠粪便中尿石素A的平均含量从31.9μg/g粪便提升至43.7μg/g粪便(p<0.05)。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种水溶性膳食纤维,其特征在于,包括以下至少两种组分:结冷胶、瓜尔胶、卡拉胶、低聚果糖、低聚木糖、低聚异麦芽糖、果胶、β-葡聚糖、聚葡萄糖、海藻酸钠、阿拉伯胶、抗性糊精、黄原胶、黄蓍胶和菊粉。
2.根据权利要求1所述水溶性膳食纤维,其特征在于,包括以下至少一组:结冷胶、瓜尔胶和卡拉胶形成的第一水溶性膳食纤维,低聚果糖、低聚木糖和低聚异麦芽糖形成的第二水溶性膳食纤维,果胶、β-葡聚糖和聚葡萄糖形成的第三水溶性膳食纤维,海藻酸钠、阿拉伯胶和抗性糊精形成的第四水溶性膳食纤维和黄原胶、黄蓍胶和菊粉形成的第五水溶性膳食纤维;
所述第一水溶性膳食纤维、第二水溶性膳食纤维、第三水溶性膳食纤维、第四水溶性膳食纤维或第五水溶性膳食纤维中三种组分的质量比依次为1~3:1~3:1~3。
3.一种促进鞣花酸代谢为尿石素A的药物组合物,其特征在于,包括权利要求1或2所述水溶性膳食纤维和鞣花酸;
所述水溶性膳食纤维和鞣花酸的质量比为(100~250):3。
4.根据权利要求3所述药物组合物,其特征在于,所述水溶性膳食纤维和鞣花酸的质量比为250:3。
5.根据权利要求3或4所述药物组合物,其特征在于,所述鞣花酸的结构式如式I所示:
6.权利要求1或2所述水溶性膳食纤维或权利要求3~5中任意一项所述药物组合物在制备促进鞣花酸代谢为尿石素A的药物中的应用。
7.一种促进鞣花酸代谢为尿石素A的产品,其特征在于,以权利要求1或2所述水溶性膳食纤维或权利要求3所述药物组合物为活性成分,还包括辅料。
8.根据权利要求7所述产品,其特征在于,所述产品包括以下至少一种:药物、保健品和保健食品。
9.权利要求1或2所述水溶性膳食纤维或权利要求3~5中任意一项所述药物组合物在制备预防和/或治疗以下至少一种疾病的药物中的应用:糖尿病、肥胖、衰老和神经中枢病变。
10.根据权利要求9所述应用,其特征在于,所述疾病的患者属于鞣花酸代谢A型人群、B型人群和/或0型人群。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310579049.6A CN116832054A (zh) | 2023-05-19 | 2023-05-19 | 一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310579049.6A CN116832054A (zh) | 2023-05-19 | 2023-05-19 | 一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116832054A true CN116832054A (zh) | 2023-10-03 |
Family
ID=88160676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310579049.6A Pending CN116832054A (zh) | 2023-05-19 | 2023-05-19 | 一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116832054A (zh) |
-
2023
- 2023-05-19 CN CN202310579049.6A patent/CN116832054A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guan et al. | Biological effects and applications of chitosan and chito-oligosaccharides | |
Sharma et al. | Moringa (Moringa oleifera Lam.) polysaccharides: Extraction, characterization, bioactivities, and industrial application | |
EP1429789B1 (de) | Antiinfektive kohlenhydrate | |
CN104619329B (zh) | 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物 | |
DE2710327C3 (de) | Verwendung von Benzaldehyd | |
CN1165315C (zh) | 关节性疾病治疗剂 | |
CN111333692A (zh) | 一种白桦脂酸衍生物及其制备方法和应用 | |
Xia et al. | Ulcerative colitis alleviation of colon-specific delivered rhamnolipid/fullerene nanocomposites via dual modulation in oxidative stress and intestinal microbiome | |
JP5714311B2 (ja) | 水難溶性薬理活性物質の薬理活性を維持しながら水溶性を付与する方法 | |
Liu et al. | Oral konjac glucomannan for prevention of ionizing radiation-induced injury by regulating gut microbiota and increasing short chain fatty acids | |
EP1879600B1 (en) | Nanotubes as mitochondrial uncouplers | |
CN116832054A (zh) | 一种水溶性膳食纤维及其在制备促进鞣花酸代谢为尿石素a的药物中的应用和药物组合物 | |
Dongre | Marine polysaccharides in medicine | |
CN105079819B (zh) | 一种抗球虫用阿德呋啉羟丙基‑β‑环糊精包合物的制备方法 | |
CA3022995C (en) | Novel ketogenic compounds, compositions, methods and use thereof | |
EA030339B1 (ru) | Композиция водорастворимых селеногликопротеинов и способ ее получения | |
KR101905863B1 (ko) | 히알루론산 나노입자를 함유하는 염증질환 및 대사질환의 예방 또는 치료용 약학 조성물 | |
US11406652B2 (en) | Use of mannuronic diacid composition in treatment of diabetes | |
JP2006206474A (ja) | 機能性食品及び医薬 | |
WO2007009393A1 (fr) | Utilisation d'acide chlorogene dans la fabrication de medicaments pour l'accroissement de l'effet de cellules de moelle osseuse | |
WO2011013999A9 (ko) | 키토올리고당을 함유하는 피로회복용 조성물 | |
DE69918680T2 (de) | Verfahren zur Erhöhung der Propionateproduktion im Gastrointestinaltrakt | |
CN112057632A (zh) | 一种复合型阿霉素脂质体及其制备方法 | |
JP2021533144A (ja) | 疼痛及び/又は発熱を予防及び/又は治療するための薬物、組成製品及びその応用 | |
RU2792613C1 (ru) | Противоопухолевые средства на основе макро- и микроэлементсодержащих полигалактуронатов (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |